CAMBRIDGE, Mass., Dec. 20, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11th, 2024 at 11:15 a.m. PST.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)

The 42nd Annual J.P. Morgan Healthcare Conference will take place January 8 – 11, 2024, in San Francisco, CA.

A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com for 30 days following the conference.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302019671.html

SOURCE Akebia Therapeutics, Inc.

Copyright 2023 PR Newswire

Grafico Azioni Akebia Therapeutics (NASDAQ:AKBA)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Akebia Therapeutics
Grafico Azioni Akebia Therapeutics (NASDAQ:AKBA)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Akebia Therapeutics